The regulator said in a statement that early data about the Abbott ID Now test suggested it could produce potentially inaccurate results, particularly by failing to detect people who have the illness.

A bitter shareholder row at China's largest property developer is a first big test for the country's new securities chief, appointed earlier this year to heal the wounds of last year's stock ...